Categories AlphaGraphs, Earnings, Health Care

A visual dashboard of Amgen’s (AMGN) Q1 2020 earnings results

Amgen’s (NASDAQ: AMGN) top and bottom line in the first quarter of 2020 beat analysts’ estimates. The biotech firm’s adjusted earnings per share surged 17% to $4.17, driven by increased revenues and fewer weighted-average shares outstanding. Revenue rose 11% annually to $6.2 billion. AMGN stock was trading up about 1% during the extended-hours.

GAAP earnings per share decreased 3% to $3.07 in the first quarter. Product sales increased 12% globally, driven by volume growth across a number of Amgen’s newer products.

Amgen (AMGN) Q1 2020 Earnings Infograph

Amgen reaffirmed its 2020 revenue guidance of $25.0 billion to-$25.6 billion. GAAP EPS guidance was revised to a range of $10.65 to $11.45 and the company maintained the non-GAAP EPS outlook of $14.85-$15.60.

Amgen announced that Otezla, an oral treatment approved in more than 50 countries for inflammatory diseases such as psoriasis and psoriatic arthritis, will be investigated as a potential immunomodulatory treatment in adult patients with COVID-19 in upcoming platform trials.

Most Popular

Key highlights from Deere & Co.’s (DE) Q4 2024 earnings results

Deere & Company (NYSE: DE) reported its fourth quarter 2024 earnings results today. Worldwide net sales and revenues decreased 28% year-over-year to $11.14 billion. Net income was $1.24 billion, or

NVDA Earnings: Nvidia Q3 profit jumps, beats estimates

NVIDIA Corporation (NASDAQ: NVDA) on Wednesday reported a sharp increase in adjusted profit and revenue for the third quarter of 2025. Earnings also topped analysts' estimates. The tech firm’s revenues

Lowe’s Companies (LOW): A few points to note about the Q3 2024 performance

Shares of Lowe’s Companies, Inc. (NYSE: LOW) rose over 1% on Wednesday. The stock has gained 8% over the past three months. The company delivered better-than-expected earnings results for the

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top